Tertiapin-Q

910044-56-3

C106H175N35O24S4

10 mM in DMSO

Membrane Transporter/Ion Channel

Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir_1.1). IC50 & Target: Potassium channel^[1] In Vitro: Tertiapin-Q is a highly selective blocker of G protein-coupled inwardly rectifying potassium (GIRK1/4) heterodimer and renal outer medullary potassium channel (ROMK1, Kir_1.1)^[1]. Tertiapin-Q is a potent and selective blocker for Kir_1.1 renal outer medullary potassium, Kir_3.1-Kir_3.4 channels and calcium activated large conductance potassium channels (big potassium channels). The somatostatin (SS-14)-activated current is almost completely blocked (93.2+/-2.9%, n=5; P<0.01) by preincubation with the G protein-coupled inwardly rectifying potassium (GIRK) channel blocker Tertiapin-Q (TPN-Q)^[2]. In Vivo: Tertiapin-Q is a muscarinic acetylcholine receptor-operated K⁺ current (I_{K, Ach}) blocker. After the cessation of rapid atrial pacing, the atrial effective refractory period (AERP) is unchanged during the experimental period in the rapid atrial pacing (RAP) rabbits (n=6). Bepridil (1 mg/kg, n=5 for each group), Amiodarone (10 mg/kg, n=5 for each group), Vernakalant (3 mg/kg, n=5 for each group), Ranolazine (10 mg/kg, n=6 for each group) or Tertiapin-Q (0.03 mg/kg, n=5 for each group) on the AERP in the control and RAP rabbits. Tertiapin-Q significantly prolongs the AERP at each pacing cycle length both in the control and RAP rabbits. The extents of prolonging effect of Tertiapin-Q on the AERP in the RAP rabbits are greater than those in the control animals^[3].